Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F BERTHAULT

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Diabetes|September 1, 1997
Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa ratS Hallakou, L Doaré, F Foufelle, et al.
Chemosphere|September 25, 2003
Evaluation of EU risk assessments existing chemicals (EC Regulation 793/93)C W M Bodar, F Berthault, J H M de Bruijn, et al.
Diabetologia|May 26, 2010
The suppressor of cytokine signalling 2 (SOCS2) is a key repressor of insulin secretionP Lebrun, E Cognard, P Gontard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 16, 2002
A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinomaM Ducreux, P Rougier, J-P Pignon, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Diabetes|September 1, 1997
Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa ratS Hallakou, L Doaré, F Foufelle, et al.
Chemosphere|September 25, 2003
Evaluation of EU risk assessments existing chemicals (EC Regulation 793/93)C W M Bodar, F Berthault, J H M de Bruijn, et al.
Diabetologia|May 26, 2010
The suppressor of cytokine signalling 2 (SOCS2) is a key repressor of insulin secretionP Lebrun, E Cognard, P Gontard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 16, 2002
A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinomaM Ducreux, P Rougier, J-P Pignon, et al.
Pageof 3